Medicine that arrives exactly where biology needs it
BBlueBio builds targeted nanocarriers and quantum-dot biosensors at the interface of materials science and molecular biology — so powerful therapeutics stop being limited by where they can go.
- 18 nm
- Median carrier diameter
- 94%
- Target-tissue selectivity
- 31
- Peer-reviewed publications
- 7
- Active co-development programs
Collaborating with research-led partners
Four capabilities, one integrated nanomedicine stack
Each layer is developed in-house, which means a payload can move from carrier design to GMP supply without leaving our facility or losing characterisation data.
BrilliantCore™ nanocarriers
Ionizable lipid nanoparticles tuned at the ångström level for endosomal escape, giving mRNA and siRNA payloads a clean path into the cytosol.
LigandMap™ targeting
A screening engine that pairs aptamers and affibodies with surface receptors, then validates biodistribution in organ-on-chip models before animal work.
Quantum-dot biosensing
Cadmium-free quantum dots detect protein biomarkers at femtomolar concentrations, turning a benchtop reader into a diagnostic-grade instrument.
Microfluidic GMP supply
Continuous-flow mixing scales from 5 mL research batches to 50 L clinical lots with a polydispersity index that stays under 0.09.
Therapeutic areas we are advancing
Our carriers are designed around the biological barrier they must cross, not adapted from a single generic formulation.
Oncology
Tumour-selective delivery
Charge-shifting carriers stay inert in circulation and activate in the acidic tumour microenvironment, sparing healthy tissue.
Immunology
Self-amplifying vaccines
Thermostable formulations hold potency for 30 days at 4 °C, removing the ultra-cold chain from distribution planning.
Neurology
Blood–brain barrier transit
Transferrin-receptor shuttles carry oligonucleotide payloads into the CNS at concentrations conventional carriers cannot reach.
From target hypothesis to clinical supply
A staged programme with clear decision gates, so partners know what they learn and when.
Target definition
Receptor mapping, payload feasibility and a go/no-go readout in six weeks.
Carrier engineering
Design-of-experiments across lipid ratios, PEG density and surface ligands.
Preclinical validation
Organ-on-chip, then in-vivo biodistribution, toxicology and potency panels.
GMP transfer
Continuous-flow scale-up, release testing and regulatory documentation.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.